NasdaqGS - Nasdaq Real Time Price USD
Sanofi (SNY)
At close: October 16 at 4:00 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 4 | 4 |
| Avg. Estimate | 1.39 | 1.11 | 4.25 | 4.91 |
| Low Estimate | 1.39 | 1.11 | 4.15 | 4.66 |
| High Estimate | 1.39 | 1.11 | 4.41 | 5.12 |
| Year Ago EPS | 2.77 | 0.89 | 4.38 | 4.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 4 | 13 | 13 |
| Avg. Estimate | 13.94B | 13.25B | 51.56B | 54.98B |
| Low Estimate | 13.69B | 12.79B | 49.51B | 51.99B |
| High Estimate | 14.44B | 13.81B | 54B | 58.32B |
| Year Ago Sales | 12.63B | 11.75B | 46.57B | 51.56B |
| Sales Growth (year/est) | 10.40% | 12.80% | 10.70% | 6.60% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | 1.37 | 0.91 | 0.94 | 0.86 |
| EPS Actual | 2.77 | 0.89 | 0.97 | 0.93 |
| Difference | 1.4 | -0.02 | 0.03 | 0.07 |
| Surprise % | 102.20% | -2.20% | 3.20% | 8.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.39 | 1.11 | 4.25 | 4.91 |
| 7 Days Ago | 1.4 | 1.12 | 4.27 | 4.93 |
| 30 Days Ago | 1.44 | 1.07 | 4.27 | 4.96 |
| 60 Days Ago | 1.49 | 0.87 | 4.19 | 4.87 |
| 90 Days Ago | 1.5 | 0.88 | 4.2 | 4.88 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | SNY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -49.80% | -- | -- | 4.40% |
| Next Qtr. | 24.70% | -- | -- | 7.80% |
| Current Year | -3.00% | -- | -- | 2.50% |
| Next Year | 15.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 9.00% | -- | -- | 11.89% |
| Past 5 Years (per annum) | 9.30% | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Argus Research: Buy | 3/27/2023 |
| Upgrade | Deutsche Bank: Sell to Hold | 8/12/2022 |
| Upgrade | SVB Leerink: Market Perform to Outperform | 9/27/2021 |
| Initiated | Deutsche Bank: Sell | 1/15/2021 |
| Upgrade | Goldman Sachs: Neutral to Buy | 3/11/2020 |
| Maintains | Argus Research: Buy | 2/19/2020 |
Related Tickers
AZN AstraZeneca PLC
78.31
+0.59%
NVS Novartis AG
116.57
+0.30%
GSK GSK plc
39.21
+0.64%
RHHBY Roche Holding AG
39.05
-0.64%
GILD Gilead Sciences, Inc.
86.75
+1.08%
BMY Bristol-Myers Squibb Company
53.37
+1.16%
AMGN Amgen Inc.
321.63
-1.06%
BIIB Biogen Inc.
189.00
-1.33%
MRK Merck & Co., Inc.
110.42
-1.00%
OGN Organon & Co.
17.94
-0.55%